Optometrists who want to include genetic testing in their AMD work-ups have a new option to consider. Start-up company Visible Genomics has launched a test that helps clarify a patient’s likelihood of developing AMD, according to a press release. The company estimates that up to 70% of AMD cases have a genetic component. The test is recommended for people who have a family history of the disease or those showing signs of early or intermediate AMD.
The saliva-based test captures the patient’s genetic status, which is then combined with ocular findings and demographic and lifestyle characteristics in the Visible Genomics risk assessment. The results, the company says, could shed light on an AMD patient’s progression risk and the lifetime risk of those with affected family members. Visible Genomics says it hopes identification of such risks can pave the way for earlier intervention, ultimately improving the patient’s long-term visual prognosis.
For more information visit Visible Genomics.